Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
Recurrent Pregnancy Loss
About this trial
This is an interventional treatment trial for Recurrent Pregnancy Loss
Eligibility Criteria
Inclusion Criteria:
- History of 2 or more unexplained recurrent miscarriage.
- Child bearing period (18-35 years old).
- Non pregnant state.
- Regular menstrual cycles for the previous three months before the study.
- No hormonal contraception or intrauterine device.
- impaired uterine artery blood flow (PI >2.02) (Mansour et al., 2018).
Exclusion Criteria:
1-Having any possible causes of abortion: anatomical, genetic, endocrinological, infectious, or immunological.
2- Autoimmune disorders which may affect blood vessels and their blood flow (systemic lupus).
3- Systemic disease that might affect the hemodynamic indices (e.g. thrombocytopenia, thyrotoxicosis … etc.).
4- Diagnosed or treated thrombophilia. 5- Any vascular disease (e.g. coronary artery disease). 6- History of oophorectomy. 7- History of consanguinity. 8- Family history of chromosomal abnormalities (e.g. trisomy 21, trisomy 13… etc.).
Sites / Locations
- Ain shams university maternity hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
sildenafil citrate
placebo
Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.